Reach Us +1-217-403-9671
The Role Of Scientific Justification In The Nascent US Biosimilars Approval Pathway | 8155
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

The role of scientific justification in the nascent US biosimilars approval pathway

International Conference and Exhibition on Biowaivers & Biosimilars

Ben Kaspar

ScientificTracks Abstracts: J Bioequiv Availab

DOI: 10.4172/0975-0851.S1.002

The term ?scientific justification? is used 15 times in the FDA Guidance for Industry entitled ?Scientific Considerations in Demonstrating Biosimilarity to a Reference Product.? Approaches to biosimilar development requiring justification include minor protein alterations, duration of immunogenicity studies, and the types of clinical trials to be conducted based on available sponsor and innovator data. Frequent mention of scientific justification suggests that, in the absence of mechanisms to establish the identical character of a biosimilar and innovator, the quality of existing data will impact clinical trial requirements. Openness to scientific discussion creates an opportunity to review the specific evidentiary needs of each biosimilar with the Agency and to tailor development programs accordingly. It also creates an implicit partnership between sponsors and the FDA in developing scientifically sound approaches to biosimilar approval. Meeting this partnership challenge requires effective scientific dialog with the FDA. Herein we review the specific instances where scientific justification is mentioned in the recent FDA Guidance with an emphasis on obtaining maximum leverage from available data to focus and drive clinical development. We compare and contrast the proposed biosimilars pathway with international guidelines and the 505(b)2 pathway, a regulatory mechanism established for comparison of variant small molecule drugs with innovators. In addition, we illustrate a number of development scenarios including how data from previous approval of a biosimilar in Europe may affect the direction of additional clinical trials. We conclude that sponsors must prepare for and lead scientific discussion to successfully navigate the nascent US biosimilars pathway
Ben Kaspar obtained his Master?s degree in Biochemistry from Case Western Reserve University in 2008. He is a regulatory strategist and writer at MMS Holdings Inc., Canton, MI. Ben has worked on multiple regulatory scenarios involving biosimilars and co-authored a recent manuscript on the future of biosimilars regulation in the United States that was published in the Journal Clinical Therapeutics.